Safety of Semaglutide
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety c...
Guardado en:
Autores principales: | Mark M. Smits, Daniël H. Van Raalte |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c006b197be31425dac88ecfb77dea26f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021) -
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson S, et al.
Publicado: (2019) -
Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
por: Kutoh Eiji, et al.
Publicado: (2019) -
Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
por: Khoury Johad, et al.
Publicado: (2018) -
Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
por: Hua-Xing Huang, et al.
Publicado: (2021)